Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 6
Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies
Experts discuss when to consider chimeric antigen receptor T-cell therapy (CAR T) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients and how to sequence CAR T and pirtobrutinib in clinical practice for those who have previously received both covalent Bruton tyrosine kinase (cBTK) inhibitor– and BCL2 inhibitor–containing regimens.
Video Player is loading.
Video content above is prompted by the following:
- Shifting focus to CLL, Dr Riedell,at what point do you consider CAR T-cell therapy for your R/R CLL patients?
- How do you sequence between CAR T and pirtobrutinib in your clinical practice for those who have previously received both cBTK inhibitor– and BCL2 inhibitor–containing regimens?